Company intelligence / Profile preview

Veluca

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

Veluca Pharmaceuticals is a biotechnology company focused on developing first-in-class small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting KIF18A, a kinesin motor protein that is essential for the survival of chromosomally unstable (CIN) cancer cells. By inhibiting KIF18A, Veluca aims to selectively induce cell death in tumors with high levels of chromosomal instability while sparing healthy cells. Their lead program, VLU-101, is currently in pre-clinical development for various solid tumors, including breast and ovarian cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Veluca.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veluca.

Explore the full profile